ProteoNic Biotechnology has licensed a vector gene delivery system to Horizon Discovery in a deal it hopes will attract firms looking to eliminate methionine sulphoximine from CHO cell selection processes.
Beijing-based Sinobioway and US biotech company BioAtla have selected the first conditionally active biologics (CABs) they will work on under a co-development deal.
UK researchers have created “designer” amino acids which they say will allow them to build custom biologics from the ground up and avoid the pitfalls of recombinant expression.
The US Food and Drug Administration (FDA) has issued guidance on biologics exclusivity, stipulating the evidence drugmakers must provide to ensure a 12-year exclusivity period.
As the race to develop mAbs (monocolonal antibodies) heats up and companies vie for the elusive seven years exclusivity that comes with an orphan drug designation, the US FDA is now offering guidance on when two mAbs should be viewed as the same.
Janssen has asked Novozymes Biopharma to help it reduce drug dosage “from daily to every two weeks or monthly” using its half-life extension technology.
Ajinomoto says its flexible approach to tech licensing differs from rivals who are more focused on locking customers into manufacturing services contracts.
Pharma supply chain consortium Rx-360 has advised drugmakers to check their L-Arginine stocks, warning that a recent surge in demand could limit supplies.
Cell penetration and pharmacodynamics boosting “stapled peptide” tech wins Aileron Therapeutics potential billion dollar protein drug development deal with Roche.